Meeder Asset Management Inc Global Blood Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$24.9 - $40.26 $473 - $764	-19 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$52.76 - $74.49 $1,002 - $1,415	19 New	19 $1,000
Q2 2020 Aug 11, 2020	SELL	$48.73 - $81.82 $1,949 - $3,272	-40 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$41.72 - $87.2 $333 - $697	-8 Reduced 16.67%	40 $2,000
Q4 2019 Feb 13, 2020	BUY	$45.7 - $81.86 $365 - $654	8 Added 20.0%	48 $4,000
Q1 2019 Apr 16, 2019	SELL	$39.99 - $53.48 $10,997 - $14,707	-275 Reduced 87.3%	40 $2,000
Q4 2018 Jan 17, 2019	BUY	$31.54 - $46.67 $9,935 - $14,701	315 New	315 $13,000
Q3 2018 Nov 02, 2018	SELL	$38.0 - $51.1 $5,206 - $7,000	-137 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$38.7 - $50.15 $19,969 - $25,877	-516 Reduced 79.02%	137 $0
Q1 2018 May 03, 2018	BUY	$39.6 - $65.9 $22,017 - $36,640	556 Added 573.2%	653 $32,000
Q4 2017 Feb 02, 2018	BUY	$29.7 - $45.7 $1,069 - $1,645	36 Added 59.02%	97 $4,000
Q3 2017 Oct 20, 2017	BUY	$25.1 - $31.05 $1,531 - $1,894	61	61 $2,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.